EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Creo Medical Group's Enterprise Value is $75.54 Mil.
Creo Medical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-26.50 Mil. Therefore, Creo Medical Group's EV-to-FCF for today is -2.85.
The historical rank and industry rank for Creo Medical Group's EV-to-FCF or its related term are showing as below:
CMEOF'
s EV-to-FCF Range Over the Past 10 Years
Min: -18.74 Med: -2.48 Max: -0.27
Current: -2.86
During the past 11 years, the highest EV-to-FCF of Creo Medical Group was -0.27. The lowest was -18.74. And the median was -2.48.
CMEOF's EV-to-FCF is ranked worse than 100% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.67
vs CMEOF: -2.86
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Creo Medical Group (OTCPK:CMEOF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Creo Medical Group's PE Ratio (TTM) for today is calculated as:
Creo Medical Group's share price for today is $0.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Creo Medical Group EV-to-FCF Related Terms
Creo Medical Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's EV-to-FCF falls into.
Creo Medical Group's current Enterprise Value is $75.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-26.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (CMEOF) has a EV-to-FCF of -2.85 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #999999 out of 419 companies in the Medical Devices & Instruments industry.
Is Creo Medical Group's EV-to-FCF too high?
Creo Medical Group's current EV-to-FCF is -2.85. Based on the distribution chart, Creo Medical Group ranks #999999 out of 419 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #999999 out of 419 companies for EV-to-FCF. This places Creo Medical Group in the lower half of its industry. The industry median EV-to-FCF is 22.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.67, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current EV-to-FCF is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current EV-to-FCF of -2.85. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current EV-to-FCF is -2.85. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current EV-to-FCF is -2.85 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
EV-to-FCF: -2.85
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
